Wednesday, July 8, 2026

biotech · Pulmonary Disease, Chronic Obstructive · Symptomatic Neurogenic Orthostatic Hypertension · TBPH

Theravance Biopharma Ireland

Theravance Biopharma Ireland is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker TBPH. Primary therapeutic focus areas include Pulmonary Disease, Chronic Obstructive, Sympt

901 Gateway Blvd., South San Francisco, CA 94080, US HQ
2014 Founded
177 Employees
Public company Type
TBPH · NYSE Ticker
Company details
Status
Public
HQ
901 Gateway Blvd., South San Francisco, CA 94080, US
Founded
2014
Employees
177
Programs
57
Drugs
18
Patents
635
Clinical program

TD-8236

Phase 2 · small molecule · Asthma

TD-8236 for Asthma is a Phase 2 program (small_molecule) at Theravance Biopharma Ireland Umited with 2 ClinicalTrials.gov record(s).

Internal code 0178

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Theravance Biopharma Ireland Umited
Phase
Phase 2
Modality
small_molecule
Indication
Asthma
Status
completed
Trials
2

Clinical trials